O
Otto C. Boerman
Researcher at Radboud University Nijmegen
Publications - 358
Citations - 17532
Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer
Marika H Tesselaar,Thomas Crezee,Imke Schuurmans,Danny Gerrits,James Nagarajah,Otto C. Boerman,Ilse van Engen-van Grunsven,Johannes W. A. Smit,Romana T. Netea-Maier,Theo S. Plantinga +9 more
TL;DR: DLCs could represent a promising adjunctive therapy for restoring iodide avidity within the full spectrum from RAI-refractory dedifferentiated to ATC.
Journal ArticleDOI
Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor.
Bart Cornelissen,Veerle Kersemans,Ingrid Burvenich,Ruth Oltenfreiter,Jean-Luc Vanderheyden,Otto C. Boerman,Christophe Vandewiele,Guido Slegers +7 more
TL;DR: 99mTc-HYNIC-hEGF is a promising and selective new radiotracer for in-vivo monitoring of the EGF receptor with SPECT and is a possible tool for early therapy response prediction of farnesyltransferase inhibitors.
Journal ArticleDOI
Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model
Laura K. van Dijk,Otto C. Boerman,Gerben M. Franssen,Jasper Lok,Johannes H.A.M. Kaanders,Johan Bussink +5 more
TL;DR: EGFR accessibility can be visualized with 111In-cetuximab-F(ab′)2 SPECT before and after radiotherapy, implying that the tracer can be used to measure irradiation-induced changes of EGFR expression and can monitor the compensatory response of tumors to radiotherapy.
Journal ArticleDOI
Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
J.C. Oosterwijk-Wakka,Mirjam de Weijert,Gerben M. Franssen,William P.J. Leenders,Jeroen van der Laak,Otto C. Boerman,Peter F.A. Mulders,Egbert Oosterwijk +7 more
TL;DR: Data indicate that sunitinib can be combined with Girentuximab, and since these two modalities have different modes of action, this combination might lead to enhanced therapeutic efficacy.
Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin
Gabie de Jong,Thijs Hendriks,Wim J.G. Oyen,Sandra Heskamp,Annemarie Eek,Robert P. Bleichrodt,Otto C. Boerman +6 more
TL;DR: In this paper, the authors evaluated the efficacy of radioimmunotherapy (RIT) with a radiolabeled monoclonal antibody (mAb) to treat experimental colorectal liver metastases.